2026 Global: Cancer Immunotherapy-Competitive Review (2032) report
Description
The 2026 Global: Cancer Immunotherapy-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer immunotherapy by geography and historical trend. The scope of the report extends to sizing of the cancer immunotherapy market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Merck & Co., Bristol Myers Squibb, Roche, Novartis, Gilead Sciences (Kite), Pfizer, AstraZeneca, Amgen, Moderna, and BioNTech are among the ten major companies shaping cancer immunotherapy through checkpoint inhibitors, cellular therapies, oncolytic and personalized vaccines, and combination strategies. Merck’s KEYTRUDA (pembrolizumab) remains a linchpin in checkpoint blockade across multiple tumor types and continues to drive the company’s oncology leadership as a broadly approved PD‑1 inhibitor. Bristol Myers Squibb advanced the field with both CTLA‑4 and PD‑1/PD‑L1 directed agents and expanded into engineered cell therapies and combinations that target resistant tumors. Roche (Genentech) leverages PD‑L1 inhibitors alongside antibody–drug conjugates and immune‑modulating antibodies to deliver multi‑modal regimens in lung, breast, and hematologic cancers. Novartis pairs landmark CAR‑T products with next‑generation cellular platforms to address hematologic malignancies and is investing in allogeneic and solid‑tumor approaches. Gilead Sciences, via Kite Pharma, is a leader in autologous CAR‑T therapies with marketed products and an active pipeline aiming to broaden indications and improve safety and durability of responses.
Pfizer and AstraZeneca contribute through checkpoint inhibitors, bispecific antibodies, and combinations with targeted agents to expand immunotherapy benefits across solid tumors. Pfizer’s oncology strategy combines immune checkpoint research with targeted and antibody programs to push combination regimens and new indications. AstraZeneca advances immuno‑oncology by integrating PD‑L1 blockade with targeted agents and antibody–drug conjugates, exemplified by its growing oncology portfolio and substantial global reach. Amgen focuses on bispecific T‑cell engagers, oncolytic viruses, and biologics that stimulate innate and adaptive immunity, aiming to convert immunologically “cold” tumors into inflamed, treatable lesions. Moderna and BioNTech, pioneers of mRNA technology, have rapidly translated their platforms into neoantigen and personalized cancer vaccine programs that aim to prime tumor‑specific T cell responses and synergize with checkpoint inhibitors, representing a new frontier in individualized immunotherapy.
These companies’ strategies converge on three priorities: improving efficacy in solid tumors, reducing immune‑related toxicity, and expanding durable responses to earlier disease settings. Large pharmaceutical players leverage established checkpoint franchises to fund discovery and external collaborations that accelerate cell‑based, bispecific, and vaccine modalities. Kite (Gilead), Novartis, and Bristol Myers Squibb continue to iterate on CAR‑T design, manufacturing scale‑up, and outpatient delivery models to increase accessibility and reduce cost of care. mRNA companies and neoantigen vaccine developers partner with checkpoint and targeted therapy teams to test rational combinations intended to overcome primary resistance and induce long‑term immune memory.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer immunotherapy by geography and historical trend. The scope of the report extends to sizing of the cancer immunotherapy market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Merck & Co., Bristol Myers Squibb, Roche, Novartis, Gilead Sciences (Kite), Pfizer, AstraZeneca, Amgen, Moderna, and BioNTech are among the ten major companies shaping cancer immunotherapy through checkpoint inhibitors, cellular therapies, oncolytic and personalized vaccines, and combination strategies. Merck’s KEYTRUDA (pembrolizumab) remains a linchpin in checkpoint blockade across multiple tumor types and continues to drive the company’s oncology leadership as a broadly approved PD‑1 inhibitor. Bristol Myers Squibb advanced the field with both CTLA‑4 and PD‑1/PD‑L1 directed agents and expanded into engineered cell therapies and combinations that target resistant tumors. Roche (Genentech) leverages PD‑L1 inhibitors alongside antibody–drug conjugates and immune‑modulating antibodies to deliver multi‑modal regimens in lung, breast, and hematologic cancers. Novartis pairs landmark CAR‑T products with next‑generation cellular platforms to address hematologic malignancies and is investing in allogeneic and solid‑tumor approaches. Gilead Sciences, via Kite Pharma, is a leader in autologous CAR‑T therapies with marketed products and an active pipeline aiming to broaden indications and improve safety and durability of responses.
Pfizer and AstraZeneca contribute through checkpoint inhibitors, bispecific antibodies, and combinations with targeted agents to expand immunotherapy benefits across solid tumors. Pfizer’s oncology strategy combines immune checkpoint research with targeted and antibody programs to push combination regimens and new indications. AstraZeneca advances immuno‑oncology by integrating PD‑L1 blockade with targeted agents and antibody–drug conjugates, exemplified by its growing oncology portfolio and substantial global reach. Amgen focuses on bispecific T‑cell engagers, oncolytic viruses, and biologics that stimulate innate and adaptive immunity, aiming to convert immunologically “cold” tumors into inflamed, treatable lesions. Moderna and BioNTech, pioneers of mRNA technology, have rapidly translated their platforms into neoantigen and personalized cancer vaccine programs that aim to prime tumor‑specific T cell responses and synergize with checkpoint inhibitors, representing a new frontier in individualized immunotherapy.
These companies’ strategies converge on three priorities: improving efficacy in solid tumors, reducing immune‑related toxicity, and expanding durable responses to earlier disease settings. Large pharmaceutical players leverage established checkpoint franchises to fund discovery and external collaborations that accelerate cell‑based, bispecific, and vaccine modalities. Kite (Gilead), Novartis, and Bristol Myers Squibb continue to iterate on CAR‑T design, manufacturing scale‑up, and outpatient delivery models to increase accessibility and reduce cost of care. mRNA companies and neoantigen vaccine developers partner with checkpoint and targeted therapy teams to test rational combinations intended to overcome primary resistance and induce long‑term immune memory.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
